Our sample was far too small and too heterogeneous regarding the variety of comorbid disorders for such subgroup analyses.

4. We did include psychometric assessments. Actually, an article on psychometric data in the same sample has already been published. This article also reports on potentially individual changes on the psychometric level.

In conclusion, ADHD is in itself a heterogeneous disorder, making the title of the article not misleading. Further, this study addresses the efficacy of EEG neurofeedback on behavioral and global clinical functioning. The clinical points reflect the results of this research question, which are supported by a recent meta-analysis, and include a direction for future research regarding subgroups. Thus, the title and the clinical points seem accurately chosen, and adjustments are therefore regarded as unnecessary.

REFERENCES


Martine van Dongen-Boomsma, MD
m.vandongen-boomsma@karakter.com

Madeon A. Vollebregt, MSc

Dorine Sluats-Willemse, PhD

Jan K. Buitelaar, MD, PhD

Author affiliations: Karakter Child and Adolescent University Centre, Nijmegen, Gelderland, The Netherlands (all authors); and Department of Cognitive Neuroscience (Dr van Dongen-Boomsma, Prof Buitelaar, and Ms Vollebregt) and Department of Psychiatry (Dr Sluats-Willemse and Dr van Dongen-Boomsma), Radboud University Nijmegen Medical Center and Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, The Netherlands.

Potential conflicts of interest: Dr Buitelaar has, in the past 3 years, been a consultant to, member of the advisory board of, and/or speaker for Janssen-Cilag, Eli Lilly, Bristol-Myers Squibb, Schering-Plough, UCB, Shire, Novartis, and Servier. He is not an employee of or a stock shareholder in any of these companies. He has no other financial or material support, including expert testimony patents, or royalties, to report. Drs van Dongen-Boomsma and Sluats-Willemse and Ms Vollebregt have no financial disclosure or potential conflicts of interest to declare.

Funding/support: The study referred to in this letter was part of BrainGain, a brain-computer interface program funded by the Netherlands Organisation for Scientific Research (NOW) and awarded to Dr Buitelaar.